Certara Expands Partnership with Merck to Advance Metadata and Data Standards Management

Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of...

July 09, 2025 | Wednesday | News
Orchard Therapeutics Completes Global Enrollment in Pivotal MPS-IH Gene Therapy Trial Ahead of Schedule

Orchard Therapeutics, a Kyowa Kirin company, announced the last patient has been treated in a registrational trial evaluating the efficacy and safety of ...

July 08, 2025 | Tuesday | News
PulseSight Therapeutics Doses First Patient in Phaase I Trial for First-in-Class Dry AMD Gene Therapy, PST-611

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery techn...

July 08, 2025 | Tuesday | News
Masitinib Receives FDA and EMA Authorisation for Confirmatory Phase 3 Trial in Metastatic Castrate-Resistant Prostate Cancer

MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3 TRIAL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER, WITH BIOMARKER-DRIVEN PATIE...

July 07, 2025 | Monday | News
Abinopharm Reports Positive Clinical Trial Outcomes for Oral Dr.Ergo® L-Ergothioneine in Enhancing Skin Health

Abinopharm, Inc., an innovative nutritional and biopharmaceutical company based in Shelton, Connecticut, USA, is pleased to announce that its partner, EG...

July 07, 2025 | Monday | News
Ferring Pharmaceuticals Announces ESHRE Data Confirming Conventional FSH Dosing for Rekovelle® Matches Follitropin Alfa in IVF

Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing for Rekovelle® (fol...

July 03, 2025 | Thursday | News
Asahi Kasei Pharma Begins Phase III Trial in Japan of ART-123 for Preventing Chemotherapy-Induced Peripheral Neuropathy

Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan (generic name: thrombomodulin alfa; marketed as Recomod...

July 03, 2025 | Thursday | News
JCR Pharmaceuticals Completes Enrollment in Global Phase III Trial of JR-141 for Hunter Syndrome Across the U.S., Latin America, and Europe

-JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) announced that it achieved the enrollment of the target number of participants in the global Phase III cli...

July 03, 2025 | Thursday | News
MaaT Pharma and Clinigen Sign Exclusive European Licensing Deal for Xervyteg® in Acute Graft-Versus-Host Disease

MaaT Pharma and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg® (MaaT013),...

July 03, 2025 | Thursday | News
WeightWatchers Expands Collaboration With Novo Nordisk to Boost Access to FDA-Approved Wegovy® at Special Pricing

WeightWatchers Clinic Members Can Access FDA-Approved Wegovy® for $299 in July, a $200 Savings Offer to Improve Access as WeightWatchers’ Trust...

July 02, 2025 | Wednesday | News
ReproNovo Doses First Participant in Phase 2 Trial of RPN-001, a Novel Oral Therapy for Male Infertility

RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low serum testosterone No FDA-...

July 02, 2025 | Wednesday | News
Artelo Biosciences Reports Positive First-in-Human Data for ART26.12, a First-in-Class FABP5 Inhibitor Targeting Chronic Pain

Artelo Biosciences, Inc. a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people liv...

July 01, 2025 | Tuesday | News
HUTCHMED and AstraZeneca Secure China Approval for ORPATHYS®–TAGRISSO® Combination in EGFR-Mutant NSCLC with MET Amplification

HUTCHMED (China) Limited  announces that the New Drug Application (“NDA”) for the combination of ORPATHYS® (savolitinib) and TAGRISS...

July 01, 2025 | Tuesday | News
Addex Therapeutics Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine for Autism and Neuropsychiatric Disorders

Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...

July 01, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close